Note: This document contains side effect information about antivenin (crotalidae) polyvalent. Some of the dosage forms listed on this page may not apply to the brand name CroFab.
Applies to antivenin (crotalidae) polyvalent: intravenous powder for solution
Along with its needed effects, antivenin (crotalidae) polyvalent (the active ingredient contained in CroFab) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking antivenin (crotalidae) polyvalent:
Incidence not known
Some side effects of antivenin (crotalidae) polyvalent may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to antivenin (crotalidae) polyvalent: injectable solution, intravenous powder for injection
The most common adverse events were urticaria and rash.
Very common (10% or more): Urticaria (16%), rash (11%)
Common (1% to 10%): Pruritus, cellulitis, subcutaneous nodule, ecchymosis
Postmarketing reports: Erythema, hyperhidrosis, angioedema
Allergic reaction consisted of urticaria, dyspnea, and wheezing. Serum sickness included urticaria, cough, rash, pruritus, and urticaria. Acute allergic reactions manifested as anxiety, bronchospasm, chills, edema, fever, hypotension, pruritus, rash, urticaria, voice alteration, and/or wheezing.
Common (1% to 10%): Allergic reaction, serum sickness
Postmarketing reports: Acute allergic reactions including anaphylaxis or anaphylactoid reactions, delayed allergic reaction.
Common (1% to 10%): Coagulation disorder
Postmarketing reports: Delayed or recurrent coagulopathy or thrombocytopenia, thrombocytopenia refractory to treatment, bleeding
Common (1% to 10%): Hypotension
Postmarketing reports: Tachycardia
Common (1% to 10%): General paresthesia, nervousness
Postmarketing reports: Tremor, dizziness, headache
Common (1% to 10%): Asthma, cough, increased sputum
Postmarketing reports: Tachypnea, bronchospasm, wheezing, tracheal edema, dyspnea
Common (1% to 10%): Back pain, myalgia
Postmarketing reports: Musculoskeletal chest pain, chills
Common (1% to 10%): Nausea, anorexia, circumoral paresthesia
Postmarketing reports: Tongue swelling, lip swelling
Common (1% to 10%): Chest pain, wound infection, chills
Postmarketing reports: Failure to achieve initial control, recurrent swelling refractory to treatment, prolonged hospitalization, treatment failure resulting in death, chest discomfort, swelling
Common (1% to 10%): Nervousness
Postmarketing reports: Worsening eye sight
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Crofab